Polar Capital Holdings PLC Summit Therapeutics Inc. Transaction History

Polar Capital Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $619,253 - $1.6 Million	-673,102 Reduced 10.73%	5,599,407 $5.6 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $3.45 $309,196 - $533,363	154,598 Added 2.53%	6,272,509 $15.4 Million
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $697,020 - $1.6 Million	-284,498 Reduced 4.44%	6,117,911 $16.5 Million
Q3 2021 Nov 15, 2021	SELL	$4.83 - $8.27 $2.7 Million - $4.63 Million	-559,504 Reduced 8.04%	6,402,409 $32.1 Million
Q2 2021 Aug 16, 2021	BUY	$5.15 - $8.46 $4.14 Million - $6.79 Million	803,113 Added 13.04%	6,961,913 $51.9 Million

Q1 2021 May 17, 2021	BUY	$5.17 - $11.19 $1.85 Million - $4.01 Million	358,800 Added 6.19%	6,158,800 $36.2 Million
Q4 2020 Feb 16, 2021	BUY	$3.25 - $6.0 $18.9 Million - $34.8 Million	5,800,000 New	5,800,000 $27.3 Million

107

41.3M

103K

29.9K

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.46B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.